MED
MEDIFAST INC
MEDIFAST INC historical holders
total: 3
Miller Value Partners MEDIFAST INC transactions over time
- Total transactions:
- 10
- New positions:
- 2
- Sold out:
- 2
- Added:
- 2
- Reduced:
- 4
- Held since:
- 2022 Q4
- Held for:
- 5 quarters
- Latest activity:
- 2024 Q1
Bill Miller has been an institutional investor in MEDIFAST INC (MED) since 2019 Q3. According to 2026 Q1 report, Bill Miller doesn't hold any shares. The fund/company first acquired MED in 2019 Q3, initially purchasing 679,515 shares. Bill Miller later completely sold out the position and reinvested in MED again in 2022 Q4. Since the initial investment, Miller Value Partners has made 9 more transactions in this position.
When did Bill Miller exit their MED position?
Bill Miller no longer holds MEDIFAST INC (MED). They sold off their entire position in 2024 Q1, closing out an investment that began in 2019 Q3.
When did Bill Miller first invest in MED?
Bill Miller first invested in MEDIFAST INC (MED) in 2019 Q3 at the reported quarter-end price of $103.63 per share, acquiring 679,515 shares in their initial purchase.
What is Bill Miller's average cost basis for MED?
Based on historical transaction data, Bill Miller's estimated cost basis for MEDIFAST INC (MED) is approximately $111.88 per share. This represents their average reported price* across all buy transactions.
Has Bill Miller reinvested in MED after selling?
Yes, Bill Miller has shown renewed interest in MEDIFAST INC (MED). After completely selling their position, they reinitiated an investment in 2022 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $111.88
- Weighted AVG sell price:
- $67.68
MED transactions history by Miller Value Partners
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q1
|
0.00%
|
0
|
$67.22
|
|
-100% (-42,100)
|
-1.68%
|
|
2023 Q3
|
1.98%
|
42,100
|
$74.85
|
$3,151,185
|
-6.03% (-2,700)
|
-0.13%
|
|
2023 Q1
|
0.29%
|
44,800
|
$103.67
|
$4,644,416
|
+42.22% (+13,300)
|
+0.09%
|
|
2022 Q4
|
0.23%
|
31,500
|
$115.35
|
$3,633,525
|
new
|
+0.23%
|
|
2020 Q4
|
0.00%
|
$164.45
|
-100% (-205,595)
|
|||
|
2020 Q3
|
1.34%
|
$164.45
|
-63.24% (-353,675)
|
|||
|
2020 Q2
|
3.45%
|
$138.77
|
-21.40% (-152,283)
|
|||
|
2020 Q1
|
2.86%
|
$62.50
|
-23.00% (-212,571)
|
|||
|
2019 Q4
|
3.62%
|
$109.58
|
+36.00% (+244,609)
|
|||
|
2019 Q3
|
2.85%
|
$103.63
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.